CD44 and acute lymphoblastic leukemia: To explore the benefit of high CD44 expression as a prognosis biomarker, we evaluated CD44 expression levels in a Children’s Oncology Group-Therapeutically Applicable Research to Generate Effective Treatments (COG-TARGET) cohort, which enabled the analysis of the expression profiles of 264 diagnostic human T-ALL samples [38].